SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma’s arm receives USFDA approval for generic Coreg CR

26 Oct 2017 Evaluate

Sun Pharmaceutical Industries’ wholly owned subsidiary has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Coreg CR, (carvedilol phosphate) extended release capsules, 10mg, 20mg, 40mg, 80 mg.

These generic carvedilol phosphate extended release capsules, 10mg, 20mg, 40mg, 80mg are therapeutic equivalents of GSK’s Coreg CR extended release capsules. As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.


Sun Pharma Inds. Share Price

1872.40 25.10 (1.36%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×